← Leaderboards
Ardis A Moe
University Of California Los Angeles
$3,818,378
Attributed
$3,818,378
Total exposure
25
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $272.3K · FY2005–10$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$3,818,378 · 25
By mechanism
M01$3,818,378 · 25
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Judith A Berliner$11,393,135
- Judith S. Currier$525,401,794
- Tzung K Hsiai$18,151,559
- Joseph R Pisegna$1,249,305
- Ronald T Mitsuyasu$121,811,876
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationHiv InfectionsDrug Screening /EvaluationAids TherapyResourcesUnited States National Institutes Of HealthFundingComputer Retrieval Of Information On Scientific Projects DatabaseSourceGrantResearch PersonnelInstitutionHiv-1Antiviral AgentsAidsMetabolicQuality Of LifeClinical Trial Phase ILeukocyte CountChemopreventionCytomegalovirus RetinitisSafety
Grant awards (37)
A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RI$134,498
M01 · FY2010 · RR · contact PI
PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MINOCYCLINE IN T$68,742
M01 · FY2010 · RR · contact PI
A PHASE II STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF A QUADRIVALENT HUM$5,274
M01 · FY2010 · RR · contact PI
A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RI$154,169
M01 · FY2009 · RR · contact PI
SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV$8,810
M01 · FY2009 · RR · contact PI
A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RI$240,690
M01 · FY2008 · RR · contact PI
SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV$31,623
M01 · FY2008 · RR · contact PI
A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RI$136,125
M01 · FY2007 · RR · contact PI
SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV$34,307
M01 · FY2007 · RR · contact PI
SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV$28,131
M01 · FY2006 · RR · contact PI
A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND TRIAL OF VALGANCICLOVIR PR$17,713
M01 · FY2006 · RR · contact PI
A PHASE II RANDOMIZED CONTROLLED TRIAL EVALUATING THE IMPACT OF THERAPEUTIC D$3,126
M01 · FY2006 · RR · contact PI
A TRIAL TO DETERMINE THE TIME TO DEVELOPMENT OF AIDS DEFINING COMPLICATIONS A$1,047
M01 · FY2006 · RR · contact PI
A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND TRIAL OF VALGANCICLOVIR PR$32,917
M01 · FY2005 · RR
A PHASE II RANDOMIZED CONTROLLED TRIAL EVALUATING THE IMPACT OF THERAPEUTIC D$3,292
M01 · FY2005 · RR
PHARMACOKINETIC EVALUATION OF THE EFFECTS OF RIBAVIRIN (RBV) ON ZIDOVUDINE (A$658
M01 · FY2005 · RR
A TRIAL TO DETERMINE THE TIME TO DEVELOPMENT OF AIDS DEFINING COMPLICATIONS A$658
M01 · FY2005 · RR
PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND TRIAL$8,648
M01 · FY2004 · RR
Trial to Determine the Time to Development of AIDS Def$2,470
M01 · FY2004 · RR
PHARMACOKINETICS OF RIBAVIRIN (RBV) ON ZIDOVUDINE (A...$1,236
M01 · FY2004 · RR
RANDOMIZED CONTROLLED TRIAL EVALUATING THE IMPACT OF T$617
M01 · FY2004 · RR
RHUGH IN TREATMENT OF HIV ASSOCIATED CATABOLISM &WASTING$207,266
M01 · FY2001 · RR
HIV AND CMV VIRAL BURDEN AND DEVELOPMENT OF CMV END-ORGAN DISEASE$207,266
M01 · FY2001 · RR
PHASE III TRIAL OF ORAL ISOTRETINOIN VS.OBSERVATION FOR CERVICAL DYSPLASIA$207,266
M01 · FY2001 · RR
PHASE III TRIAL OF ORAL ISOTRETINOIN VS.OBSERVATION FOR CERVICAL DYSPLASIA$207,266
M01 · FY2001 · RR
RANDOMIZED, PLACEBO CONTROLLED TRIAL TO DETERMINE EFFICACY OF AZITHROMYCIN$207,266
M01 · FY2001 · RR
RANDOMIZED, PLACEBO CONTROLLED TRIAL TO DETERMINE EFFICACY OF AZITHROMYCIN$207,266
M01 · FY2001 · RR
DISCONTINUATION OF MAINTENANCE THERAPY FOR CMV RETINITIS$207,266
M01 · FY2001 · RR
DISCONTINUATION OF MAINTENANCE THERAPY FOR CMV RETINITIS$207,266
M01 · FY2001 · RR
SP 303 FOR TREATMENT OF DIARRHEA IN AIDS PATIENTS$207,266
M01 · FY2001 · RR
RHUGH IN TREATMENT OF HIV ASSOCIATED CATABOLISM &WASTING$207,266
M01 · FY2001 · RR
OCULAR COMPLICATIONS OF AIDS: GANCICLOVIR CIDOFOVIR CMV RETINITIS$207,266
M01 · FY2001 · RR
OCULAR COMPLICATIONS OF AIDS: GANCICLOVIR CIDOFOVIR CMV RETINITIS$207,266
M01 · FY2001 · RR
HIV AND CMV VIRAL BURDEN AND DEVELOPMENT OF CMV END-ORGAN DISEASE$207,266
M01 · FY2001 · RR
PROTEASE/AND/OR REVERSE TRANSCRIPTASE INHIBITOR IN HIV T$0
M01 · FY2001 · RR
SP 303 FOR TREATMENT OF DIARRHEA IN AIDS PATIENTS$207,266
M01 · FY2000 · RR
SP 303 FOR TREATMENT OF DIARRHEA IN AIDS PATIENTS$1,903
M01 · FY2000 · RR